Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

SOPHIA ANTIPOLIS, France, November 4 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced positive top-line results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study), which compared the 24-hour blood pressure profile of escalating doses of naproxcinod and naproxen in osteoarthritis (OA) patients with controlled hypertension. The primary ABPM parameter was the mean 24-hour ambulatory systolic blood pressure (SBP) measured by ABPM over the whole study period and naproxcinod showed a statistically significant decrease in SBP of 3.8 mmHg (p=0.011) compared to naproxen. Furthermore, in contrast to naproxen, naproxcinod reduced the mean 24-hour SBP and diastolic blood pressure (DBP) from baseline at every dose comparison. Good safety and tolerability were shown by all naproxcinod doses. NicOx plans to provide further details of the results at a leading cardiology conference in 2009.

Naproxcinod is the first investigational drug in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donator (CINOD) class of anti-inflammatory agents, which is nearing the end of phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis, with the submission of a New Drug Application (NDA) with the US Food and Drug Administration (FDA) projected for mid-2009. NicOx expects to have the results of a second large ABPM study in patients with hypertension and OA (112) before the end of 2008, in addition to the results of the remaining pivotal phase 3 trial in hip OA (303).

COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen and ibuprofen, are widely used as symptomatic treatments for OA. However, they can cause new episodes of high blood pressure and destabilize previously controlled hypertensive patients, which is a particular concern in the OA population where approximately 50% of patients are estimated to be hypertensive.

"These impressive
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009).... 27 ACUO TECHNOLOGIES, developers...ware, data migration tools and services, is please...ademark Office has approved a patent application f...r Network." Acuo Technologies is pleased to add th...perty. In general, the granted patent application ...
(Date:11/26/2009)...th Africa, Nov. 26 The 2009 Frost ...ard in the Generic Pharmaceutical Market is presen...ogo: http://www.newscom.com/cgi-bin/prnh/20081117... the following criteria were used to benchmark Cip...rowth strategy and implementation, degree of innov...
(Date:11/25/2009)...ov. 25 American Scientif...y") is pleased to announce that they have opened a...ce in Shanghai, China. ,, ASR has been able to ...ateway for the development and production of curre...ren and adults to be distributed and sold globally...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4American Scientific Resources Inc. Opens Shanghai Location 2Study identifies potential fix for damaged knees 51203 1Study identifies potential fix for damaged knees 51203 2Study identifies potential fix for damaged knees 51203 3MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration 51201 1MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration 51201 2MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration 51201 3Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1
...s to be Presented at the North American Menopause ... Meeting, EMERYVILLE, Calif., Sept. 25 Bionovo, ...a presentation on their new drug,candidate, VG101,... Annual,Meeting of the North American Menopause So...r. Mary Tagliaferri, president and chief medical,o...
...ance of cleaning floor drains often underestimated...ation protocols, ATLANTA, Sept. 24 Recent media ...rs concerned about food safety. As a result of the...tailers, and food service,companies are reviewing ...ls in order to reduce the risk of food contaminati...
Other Medicine Technology:Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 2Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains 2Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains 3
(Date:11/29/2009)...get blamed for something leads to more self-defens...DAY, Nov. 29 (HealthDay News) -- The blame game is...the target is innocent. , Researchers found tha... problem, even if it,s an unfair accusation, they,...oo. , "When we see others protecting their ego...
(Date:11/28/2009)...GO, Nov. 28 Welcome to syngo&#...r the clinical routine from Siemens Healthcare. ...ons System (PACS) from Siemens where 2D, 3D, and... .plaza is poised to change the way multimodality ...nnovation at the 95th Scientific Assembly and An...
(Date:11/27/2009)...D, Mass., Nov. 27 GSI Gr...pplier of precision technology products and semico...eting of the Company,s shareholders has been sched...ation of the meeting will be announced in due cour... a requisition notice from Stephen Bershad, a hold...
(Date:11/27/2009)...ER, N.Y., Nov. 27 Preve...vider and fortunately every year, new vaccines are...do all vaccines boost immunity for the same period...r shots, needed to keep immunity strong? ,, I... the American Academy of Pediatrics, Michael Pichi...
(Date:11/27/2009)...ing unprecedented medical, economic burdens, study... News) -- The number of people with diabetes in th...t 25 years, a new study predicts. , That would ...le with the disease, up from 23.7 million today. ,... with diabetes will triple, the study also warns, ...
Breaking Medicine News(10 mins):Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3
... very optimistic about Warfarin, an anti-clotting ...in patients suffering an abnormal heart rhythm, th...scores over the present treatment of Plavix plus a...,' Oral anticoagulants such as warfarin remain the...
...Pentagon placed new restrictions on a doctors’ ro... against any policy //that gives medical professi...ters’ to use harsher tactics than they would in t...ghts groups and medical ethicists. They charge tha...
...twins Amal and Amrutha, who became orphaned after ...ll be formally adopted by the Kerala Government at...being organised by Cheruvathur Grama Panchayat to ...a recent Cabinet meeting mooted the idea of adopti...
... popular excuse "not tonight, I have a headache," ...oid sexual activity and says that sexual desire an...mical. // In fact, migraine sufferers report...d colleagues. 'Migraine patients in general m...
...as long been associated with mesothelioma and lung...gnancies as well //. The Indian Institute of...addition IOM also concluded that there was ‘sugges...fficient evidence to relate asbestos to esophageal...
...nd Healthcare products Regulatory Agency (MHRA) wa...ulty readings. The diabetic patients are cautioned...e found to giving readings which were far too high...s of insulin resulting in hypoglycaemic coma. ...
Other Medicine News:Health News:Medical Role In Interrogations Curtailed By Pentagon 2Health News:Laryngeal Cancer Added to Asbestos’ Crime Lis 2
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: